Nasdaq:AIFF
FIREFLY NEUROSCIENCE, INC.
A pre-revenue clinical-stage neuroscience company with significant cash burn and a massive accumulated deficit seeking to bring novel therapies to patients.
Key Metrics
Investment Thesis
Bull Case
Early-stage biotech investors may see potential in AIFF if the company successfully secures new funding to extend its runway beyond the current cash depletion timeline. A successful late-stage clinical trial for any of its neurological candidates could generate substantial value through partner deals or future commercialization rights. The company's focus on high-need neurological markets offers a long-term upside scenario if the pipeline progresses efficiently.
Bear Case
The stock is highly speculative given the near-zero revenue and a negative net profit of $-10.5M, making it vulnerable to immediate bankruptcy or forced liquidation without new capital injection. The sharp decline in assets and significant increase in liabilities relative to equity suggests a deteriorating balance sheet that threatens long-term solvency. Investors should avoid this stock unless they are prepared for total loss due to the lack of diversified income streams and high burn rate.
About FIREFLY NEUROSCIENCE, INC.
FIREFLY NEUROSCIENCE (AIFF) is a clinical-stage biotechnology firm focused on developing novel therapeutics for neurological disorders. The company operates primarily in the United States research and development market, leveraging its proprietary platform to advance early-stage drug candidates.
Analysis
Management Discussion
Management has faced severe headwinds as operating cash flow turned negative at $-6.2M while general and administrative expenses reached $6.1M, significantly outpacing the minimal revenue generation. The dramatic contraction in total revenue from $12.0M to $0.1M over the last two years indicates a critical pivot or failure in existing business models that requires immediate strategic correction.
Industry Overview
The global neuroscience sector is characterized by high failure rates in drug development but offers enormous potential rewards for companies that successfully navigate clinical trials. Regulatory hurdles remain steep, requiring substantial capital expenditure for R&D before any product can reach the market, a reality reflected in AIFF's current financial distress. Competition is intense among large pharmaceutical firms and smaller biotechs vying to capture share in treating Alzheimer's, Parkinson's, and other neurodegenerative conditions.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $12.0M | $8.0M | $108.0K |
| Cost of Revenue | $9.4M | $5.4M | $0 |
| Gross Profit | $2.6M | $2.6M | $108.0K |
| Operating Expenses | $21.4M | $4.4M | $10.2M |
| Operating Income | $-18.8M | $-1.8M | $-10.1M |
| R&D | — | — | $2.0M |
| G&A | $12.1M | $5.8M | $6.1M |
| Marketing | — | — | $1.2M |
| Stock-Based Comp | $2.0M | $710.5K | $2.6M |
| D&A | $1.4M | $217.2K | $67.0K |
| Depreciation | — | — | $12.0K |
| Amortization | $1.4M | $176.2K | — |
| Other OpEx | $9.3M | $-1.4M | $874.0K |
| Non-Operating Income | $-74.5K | $289.9K | $-404.0K |
| Interest Expense | $81.6K | $103.3K | — |
| Pre-Tax Income | $-18.9M | $-1.5M | $-10.5M |
| Income Tax | $-1.1M | $-42.6K | $2.0K |
| Continuing Ops | $-17.8M | $-1.7M | $-10.5M |
| Discontinued Ops | $0 | $-336.0K | $0 |
| Net Income | $-17.8M | $-2.0M | $-10.5M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-17.8M | $-2.0M | $-10.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $2.8M | $2.1M | $2.6M |
| Cash & Equivalents | $731.1K | $682.0K | — |
| Accounts Receivable | $1.6M | $1.1M | $121.0K |
| Prepaid Expenses | $442.4K | $267.4K | $697.0K |
| Other Current Assets | $0 | $0 | $1.8M |
| Long-Term Assets | $5.2M | $2.5M | $2.0M |
| PP&E (Net) | $597.4K | $58.0K | $136.0K |
| Intangibles | $3.0M | $1.0M | $180.0K |
| Goodwill | $1.1M | $1.1M | — |
| Operating Leases | $376.1K | $245.6K | — |
| Other LT Assets | $79.3K | $18.4K | $1.7M |
| Total Assets | $8.0M | $4.5M | $4.6M |
| Current Liabilities | $3.9M | $2.1M | $5.0M |
| Accounts Payable | $573.8K | $403.4K | $1.8M |
| Current Leases | $203.3K | $163.3K | — |
| Deferred Revenue | $182.8K | $114.5K | $13.0K |
| Taxes Payable | $3.1K | $3.5K | — |
| Other Current Liab | $2.9M | $1.4M | $3.1M |
| Long-Term Liabilities | $362.9K | $152.8K | $0 |
| LT Operating Leases | $303.8K | $136.7K | — |
| Other LT Liab | $-365.9K | $-483.8K | — |
| Total Liabilities | $4.3M | $2.3M | $5.0M |
| Shareholders' Equity | $3.7M | $2.3M | $-375.0K |
| Paid-In Capital | $35.9M | $36.5M | $86.7M |
| Retained Earnings | $-31.2M | $-33.2M | $-87.1M |
| Treasury Stock | $965.2K | — | — |
| Total L&E | $8.0M | $4.5M | $4.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-17.8M | $-2.0M | $-10.5M |
| Non-Cash Adjustments | $13.1M | $378.2K | $4.5M |
| Working Capital Changes | $-1.4M | $-1.2M | $-218.0K |
| Cash from Operations | $-6.0M | $-2.8M | $-6.2M |
| Capital Expenditures | $535.9K | $0 | — |
| Cash from Investing | $-535.9K | $2.3M | $-477.0K |
| Cash from Financing | $2.3M | $429.5K | $6.3M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-4.2M | $-49.1K | $-333.0K |
| Beginning Cash | $4.9M | $731.1K | $2.1M |
| Ending Cash | $731.1K | $682.0K | $1.8M |
Frequently Asked Questions
How does FIREFLY NEUROSCIENCE, INC. make money?
The company's financial profile indicates a single primary revenue stream derived from strategic collaborations or grants, evidenced by the negligible revenue of $108k against substantial R&D spending of $2.0M. Operations are concentrated in core research and development activities with no distinct commercial product lines yet generating meaningful sales.
What are the main risks for AIFF?
The company faces an existential liquidity risk with negative operating cash flow of $-6.2M and a cash balance decline from $2.1M to $1.8M, necessitating future equity financing that may dilute shareholders. The massive retained earnings deficit of $-87.1M highlights historical losses that have eroded the shareholder equity base significantly. Revenue collapse from $12.0M in 2022 to near zero in 2024 suggests a potential failure of current commercialization strategies or partnership agreements.
What is AIFF's competitive advantage?
The company holds a pipeline of proprietary neurological drug candidates that could address unmet medical needs if successfully advanced to late-stage trials. Its current financial structure includes a substantial paid-in capital base of $86.7M, providing a runway to fund research efforts despite negative operating cash flow. The organization possesses specialized expertise in neurobiology and pharmacology essential for navigating the complex regulatory landscape.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.